Remdesivir: US buys world stock of key coronavirus drug
Trump administration goes on shopping spree leaving ‘nothing for Europe’
The US has bought the global stock of the key coronavirus drug remdesivir, leaving none for the UK, Europe or most of the rest of the world.
Remdesivir is the first drug approved by licensing authorities in the US to treat Covid-19, and one of just two drugs worldwide proven to combat the virus.
The Trump administration has bought more than 500,000 doses, which is all of the production of remdesivir for July and 90% of August and September, reports The Guardian.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar.
“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19.”
The drug is under patent to Gilead, which means no other company countries can make it - and that means the US has a monopoly on the treatment.
“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.
How does it work?
US officials say there is “clear-cut” evidence that remdesivir can cut the duration of symptoms, after clinical trials in hospitals around the world found it reduced it from 15 days down to 11.
Analysts say the drug could “have the potential to save lives, ease pressure on hospitals and allow parts of lockdown to be lifted” and the New York Times says US Food and Drug Administration already has plans to announce an emergency-use authorisation for remdesivir.
The drug is an antiviral and works by attacking an enzyme that a virus needs in order to replicate inside human cells. It was originally developed as a treatment for Ebola.
–––––––––––––––––––––––––––––––For a round-up of the most important stories from around the world - and a concise, refreshing and balanced take on the week’s news agenda - try The Week magazine. Start your trial subscription today –––––––––––––––––––––––––––––––
Dr Anthony Fauci who runs the NIAID said: “The data shows remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery.”
He claimed the results prove “a drug can block this virus” and were “opening the door to the fact that we now have the capability of treating” patients.
However, Professor Babak Javid, a consultant in infectious diseases at Cambridge University Hospitals, said remdesivir “is not a magic bullet”.
Professor Mahesh Parmar, who has run the trial in Europe, also urged caution. He said: “Before this drug can be made more widely available, a number of things need to happen: the data and results need to be reviewed by the regulators to assess whether the drug can be licensed and then they need assessment by the relevant health authorities in various countries.
“While this is happening we will obtain more and longer term data from this trial, and other ones, on whether the drug also prevents deaths from Covid-19.”
Dr Maria Van Kerkhove, the World Health Organisation’s technical lead for the coronavirus response, told CNN: “Typically, you don't have one study that will come out that will be a game changer.”
A report in the Lancet says a trial of the same drug in China found it was ineffective. However, the China trial was incomplete because the success of lockdown in Wuhan meant doctors ran out of patients.
The BBC says there are several unanswered questions over the drug: “Is it allowing people who would have recovered anyway to do so more quickly? Or is it preventing people from needing treatment in intensive care?Did the drug work better in younger or older people? Or those with or without other diseases? Do patients have to be treated early when the virus is thought to peak in the body?”
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Inside Chopard's hotel on Place Vendôme
The Blend Swiss jewellery maison Chopard unveils its new jewel, an ultra-exclusive Parisian hotel that elevates the art of hospitality
By Felix Bischof Published
-
Today's political cartoons - October 14, 2024
Cartoons Monday's cartoons - Columbus Day, the death of satire, and more
By The Week US Published
-
Lonely Planet and the surge of age-gap romances
In The Spotlight Laura Dern is the latest Hollywood actor to star opposite a much younger love interest
By Irenie Forshaw, The Week UK Published
-
Why NATO, Ukraine are nervous about a second Trump presidency
The Explainer A 'radical reorientation' of U.S. policy is possible
By Joel Mathis, The Week US Published
-
Bob Woodward's War: the explosive Trump revelations
In the spotlight Nobody can beat Watergate veteran at 'getting the story of the White House from the inside'
By Chas Newkey-Burden, The Week UK Published
-
'Nobody sees themselves in the word 'other'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
Who are undecided voters, anyway?
Talking Points They might decide the presidential election
By Joel Mathis, The Week US Published
-
Donald Trump's health care plan would retain the status quo
The Explainer The Republican Party is still having difficulty formulating concrete health care proposals
By David Faris Published
-
What power does Elon Musk hold as a campaigner?
Talking Points The world's richest man is going all in to get Donald Trump elected in November — whether it will make a difference is entirely unclear
By Rafi Schwartz, The Week US Published
-
'Some of the delay is needless'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
Why does Donald Trump want to free the founder of an online black market?
Today's Big Question Ross Ulbricht was sentenced to life in prison for creating the Silk Road market
By Justin Klawans, The Week US Published